XML 59 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Mar. 21, 2016
Summary of Significant Accounting Policies (Details) [Line Items]                
Forward stock split, description     forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock   Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.      
Common stock, par value (in Dollars per share)               $ 0.001
Common stock authorized (in Shares)               360,000,000
Stock reverse split ratio     On July 25, 2023, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock.          
Cash and cash equivalents $ 500,069   $ 500,069   $ 85,265 $ 5,828,548    
Restricted cash 620,868   $ 620,868   $ 1,306,463      
Account receivable     99.76%   71.89% 33.38%    
Total revenues, percentage     81.19% 79.18%        
Impairment of equity investments     $ 0 $ 0 $ 0   $ 0  
Labor pension fund percentage     6.00%   6.00%      
Percentage of monthly contribution     6.00%   6.00%      
Employee benefits amount 2,566 $ 3,302 $ 7,825 9,948 $ 13,031 $ 11,375    
Employee stock-based compensation expenses 0 0 0 0        
Non-employee stock-based compensation expenses $ 817,740 $ 225,740 $ 1,409,969 $ 5,143,483        
Benefit percentage     50.00%   50.00%      
Restricted cash equivalents         $ 1,306,463 $ 736,667    
Total revenues percentage         93.22% 46.24%    
Employee stock-based compensation expenses         $ 1,241,930 $ 2,675,205    
Non-employee stock-based compensation expenses         5,794,848 $ 2,631,550    
Accounts Receivable [Member]                
Summary of Significant Accounting Policies (Details) [Line Items]                
Allowance for expected credit losses     $ 113,694   $ 194,957      
Board of Directors [Member]                
Summary of Significant Accounting Policies (Details) [Line Items]                
Stock reverse split ratio     On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the “Reverse Split”) of both the authorized common stock of the Company (the “Common Stock”) and the issued and outstanding Common Stock          
Biokey [Member]                
Summary of Significant Accounting Policies (Details) [Line Items]                
Account receivable         16.62%      
GenePharm, Inc [Member]                
Summary of Significant Accounting Policies (Details) [Line Items]                
Account receivable           37.48%